Insmed Incorporated · 11 hours ago
Associate Director, Business Development - Search & Evaluation, Immunology & Inflammation
United States
Full-time
Remote
Lead/Staff, Director/Executive
$164K/yr - $213K/yr
3+ years expInsmed Incorporated is a global biopharmaceutical company dedicated to transforming the lives of patients with serious and rare diseases. They are seeking an Associate Director of Business Development focused on Search & Evaluation in Immunology and Inflammation to support the development and execution of growth strategies and evaluate business opportunities.
BiotechnologyMedicalPharmaceutical
Responsibilities
Lead the evaluation of scientific and data-driven analyses and prepare written/oral summaries and presentations of the uncovered information related to new product acquisitions or merger
Proactively identify and evaluate external growth opportunities for inbound partnering/acquisition in new Immunology and Inflammation therapeutic areas
Continuously scout, monitor, and evaluate new technologies that may be of strategic interest to Insmed
Build internal and external networks to proactively identify and assess new technologies and programs in the Immunology and Inflammation therapeutic area
Participate, as needed, in evaluating early venture-like opportunities
Support and conduct strategic, market, and competitive analyses of business development opportunities, including potential acquisitions, divestitures, alliances, and strategic investments
Maintain databases of opportunities and historical records of previous evaluations
Establish external and internal networks to support market intelligence and identification of relevant business transformation opportunities for growth
Attend external partnering and scientific conferences and meetings
Qualification
Required
PhD in Biology, Cell Biology, Biochemistry, Immunology or a related discipline
3+ years' experience within the biotech/pharmaceutical arena
Strong knowledge of disease areas, drug development, activities and commercial processes
Solid understanding of product development and regulatory requirements for early, mid, and late stages assets, with ability to provide scientific support and communicate findings
Enhanced scientific acumen, understanding of R&D/clinical data, and project management skills
Experience performing scientific evaluation and diligence in support of M&A and licensing activities
Basic understanding of financial analyses and willingness to learn advanced modeling
Experience working in a matrixed team environment with the ability to work collaboratively with colleagues and external partners
Experience in presenting recommendations and influencing internal and external groups
Excellent communication (written and verbal), leadership, interpersonal and problem-solving skills
Preferred
Direct Business Development experience in pharma/biotech is a plus
Specific Immunology and/or Inflammation therapeutic area experience is strongly desired
Benefits
Comprehensive medical, dental, and vision coverage and mental health support, annual wellbeing reimbursement, and access to our Employee Assistance Program (EAP)
Generous paid time off policies, fertility and family-forming benefits, caregiver support, and flexible work schedules with purposeful in-person collaboration
401(k) plan with a competitive company match, annual equity awards, and participation in our Employee Stock Purchase Plan (ESPP), and company-paid life and disability insurance
Company Learning Institute providing access to LinkedIn Learning, skill building workshops, leadership programs, mentorship connections, and networking opportunities
Employee resource groups, service and recognition programs, and meaningful opportunities to connect, volunteer, and give back
Company
Insmed Incorporated
Insmed is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases.
1001-5000 employees
Funding
Current Stage
Public CompanyTotal Funding
$4.56BKey Investors
CureDuchenne Ventures
2025-06-11Post Ipo Equity· $750M
2024-05-30Post Ipo Equity· $650M
2023-05-08Post Ipo Equity· $0.5M
Leadership Team
Will Lewis
Chairman and Chief Executive officer
Walter R. Perkins
Chief Technology Officer
Recent News
2026-01-13
Company data provided by crunchbase